Makoto Nishio

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 957 citations · Full text

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019 · 919 citations

Open-label Phase 3, Medicine, Pathology +8

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 895 citations

Medicine, Randomised Phase 3, Pathology +8